This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock PRAN vs. BIOA, NLTX, CYBN, VIRI, WHWK, OSTX, ELYM, ATNM, NBRV, and AADIShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), and Aadi Bioscience (AADI). Alterity Therapeutics vs. Its Competitors BioAge Labs Neoleukin Therapeutics Cybin Virios Therapeutics Whitehawk Therapeutics OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Nabriva Therapeutics Aadi Bioscience BioAge Labs (NASDAQ:BIOA) and Alterity Therapeutics (NASDAQ:PRAN) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Do insiders & institutionals believe in BIOA or PRAN? 3.6% of Alterity Therapeutics shares are held by institutional investors. 20.8% of BioAge Labs shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media prefer BIOA or PRAN? In the previous week, BioAge Labs had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for BioAge Labs and 1 mentions for Alterity Therapeutics. BioAge Labs' average media sentiment score of 0.15 beat Alterity Therapeutics' score of 0.00 indicating that BioAge Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alterity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BIOA or PRAN more profitable? Alterity Therapeutics' return on equity of 0.00% beat BioAge Labs' return on equity.Company Net Margins Return on Equity Return on Assets BioAge LabsN/A -25.39% -23.22% Alterity Therapeutics N/A N/A N/A Which has higher earnings and valuation, BIOA or PRAN? Alterity Therapeutics has higher revenue and earnings than BioAge Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge LabsN/AN/A-$71.11MN/AN/AAlterity Therapeutics$150K300.94-$6.40M-$0.70-7.25 SummaryAlterity Therapeutics beats BioAge Labs on 6 of the 8 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAN vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.14M$876.45M$5.83B$10.07BDividend YieldN/A4.84%5.25%4.53%P/E Ratio-7.251.1175.6426.02Price / Sales300.9426.51534.43117.75Price / CashN/A19.5637.4259.95Price / Book3.626.7711.706.20Net Income-$6.40M-$4.20M$3.29B$270.65M Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRANAlterity TherapeuticsN/A$5.07+1.1%N/A+298.3%$45.14M$150K-7.2514Gap DownBIOABioAge LabsN/A$4.65-5.7%N/AN/A$176.74MN/A0.00N/AHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$18.48-1.9%N/A-45.2%$173.68MN/A-5.9490CYBNCybin2.3393 of 5 stars$6.24-16.6%$85.00+1,262.2%N/A$147.20MN/A-1.4250High Trading VolumeVIRIVirios TherapeuticsN/A$4.96+3.4%$5.00+0.8%+2,652.1%$95.52MN/A-18.375Gap DownWHWKWhitehawk TherapeuticsN/A$1.82+0.8%N/AN/A$85.07M$25.98M-30.3340Gap DownOSTXOS Therapies1.6652 of 5 stars$2.23-6.7%$18.00+707.2%-41.3%$70.57MN/A-2.82N/AELYMEliem TherapeuticsN/A$2.23-3.0%N/A-69.6%$66.35MN/A-4.219Gap UpATNMActinium Pharmaceuticals2.286 of 5 stars$1.73-2.8%$4.50+160.1%-13.4%$53.97MN/A-1.2430Short Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi BioscienceN/A$1.81+2.0%N/A+1.1%$44.58M$25.07M-0.7940News Coverage Related Companies and Tools Related Companies BioAge Labs Competitors Neoleukin Therapeutics Competitors Cybin Competitors Virios Therapeutics Competitors Whitehawk Therapeutics Competitors OS Therapies Competitors Eliem Therapeutics Competitors Actinium Pharmaceuticals Competitors Nabriva Therapeutics Competitors Aadi Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAN) was last updated on 9/11/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRAN Stock Alerts